Abstract

Objectives: To compare the immediate and short-term (6 months) angiographic and clinical outcomes in patients with de-novo small vessel disease (SVD) treated with drug-coated balloon (DCB) versus drug-eluting stent (DES) Methods: Sixty patients underwent percutaneous coronary revascularization of SVD (reference vessel diameter <3 mm). They were randomly assigned in a 1:1 ratio to be treated with either: SeQuent® please Neo paclitaxel-eluting DCB (30 patients) or Xience Expedition Evorolimus-eluting DES (30 patients). Angiographic (using Quantitative Coronary Angiogram) and clinical outcomes (MACE) were was assessed immediately and at 6 months follow up. Results: Patients with DES had better immediate angiographic vessel wall expansion and acute lumen gain in comparison to the DCB (1.79 ± 0.21 mm vs 1.64 ± 0.20 mm, p= 0.006). At 6 months follow up, late lumen loss was significantly less in DCB group compared to DES (0.28 ± 0.29 mm vs. 0.42 ± 0.20 mm, p=0.04). However, late minimal lumen diameter (1.81 ± 0.27mm vs. 1.83 ± 0.18 mm, p=0.881), late diameter stenosis (26.3 ± 11.5% vs. 27.7 ± 7.9%, p= 0.584), and net lumen gain (1.35 ± 0.18 mm vs. 1.37 ± 0.15 mm, p= 0.79) were similar between both groups.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call